| HCPCS | Generic Name | Brand Name | Strength | SEER*Rx Category | Major Drug Class | Minor Drug Class | Oral (Y/N) | FDA Approval Year | FDA Discontinuation Year | CMS Effective Date | CMS Discontinuation Date | Status |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J9295 | Necitumumab | Portrazza | 1 mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2015 | Jan 1, 2017 | In Use | ||
| C9235 | Panitumumab | Vectibix | 10mg | Immunotherapy | Monoclonal Antibody | EGFR | No | 2006 | Jan 1, 2007 | Dec 31, 2007 | No Longer Used | |
| Q5111 | Pegfilgrastim-cbqv | Udenyca | 0.5mg | Ancillary Therapy | Immunostimulant | Granulocyte Colony-Stimulating Factor | No | 2019 | Jan 1, 2019 | In Use | ||
| C9127 | Paclitaxel | Taxol | 1 mg | Chemotherapy | Antimitotic Agent | Taxane | No | 1992 | Jan 1, 2005 | Dec 31, 2005 | No Longer Used | |
| J9216 | Interferon Gamma-1b | Actimmune | 3 million units | Immunotherapy | Cytokine | Interferon | No | 1999 | Jan 1, 2009 | In Use | ||
| J9227 | Isatuximab-irtc | Sarclisa | 10mg | Immunotherapy | Monoclonal Antibody | CD38 | No | 2020 | Oct 1, 2020 | In Use | ||
| J9063 | Mirvetuximab soravtansine | Elahere | 1mg | Immunotherapy | Drug Antibody Conjugate | FR-alpha, DM4 | No | 2022 | Jul 11, 2023 | In Use | ||
| J0614 | Treosulfan | Grafapex | 50mg | Chemotherapy | Alkylating Agent | Alkyl Sulfonate | No | 2025 | Sep 8, 2025 | In Use | ||
| J2430 | Pamidronate disodium | Aredia | 30mg | Ancillary Therapy | Bisphosphonate | No | 1987 | In Use | ||||
| C9306 | Telisotuzumab vedotin-tllv | Emrelis | 1mg | Immunotherapy | Drug Antibody Conjugate | c-MET | No | 2025 | 2026 | Sep 8, 2025 | In Use | |
| C9454 | Pasireotide | Signifor, Signifor LAR | 1 mg | Hormonal Therapy | Somatostatin Analog | No | 2012 | Jan 1, 2016 | In Use | |||
| J1323 | Elranatamab-bcmm | Elranatamab-bcmm | 1mg | Immunotherapy | Monoclonal Antibody | BCMA, CD3 | No | 2023 | Apr 17, 2024 | In Use | ||
| C9073 | Brexucabtagene autileucel | Tecartus | 2000000 | Immunotherapy | CAR-T | CD19 | No | 2020 | Jan 1, 2021 | Apr 1, 2021 | In Use | |
| J9032 | Belinostat | Beleodaq | 10 mg | Chemotherapy | Enzyme Inhibitor | HDAC | No | 2014 | Jan 1, 2016 | In Use | ||
| J9033 | Bendamustine Hcl | Bendamustine Hcl | 1 mg | Chemotherapy | Alkylating Agent | Nitrogen Mustard | No | 2008 | Jan 1, 2009 | In Use | ||
| J0642 | Levoleucovorin | Khapzory | 0.5mg | Ancillary Therapy | Chemoprotective | Antidote | No | 2018 | Oct 1, 2019 | In Use | ||
| J9349 | Tafasitamab-cxix | MONJUVI | 2mg | Immunotherapy | Monoclonal Antibody | CD19 | No | 2020 | Apr 1, 2021 | In Use | ||
| J9350* | Topotecan | Hycamtin | 4 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | No | 1996 | Jan 1, 1998 | Dec 31, 2010 | No Longer Used | |
| J9351 | Topotecan | Hycamtin | 0.1 mg | Chemotherapy | Topoisomerase I Inhibitor | Campothecin Analogs | No | 1996 | Jan 1, 2011 | In Use | ||
| C9066 | Sacituzumab govitecan-hziy | Trodelvy | 10mg | Immunotherapy | Drug Antibody Conjugate | Trop-2 | No | 2020 | Oct 1, 2020 | Jan 1, 2021 | In Use | |
| J3263 | Toripalimab-tpzi | Loqtorzi | 1mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2023 | Jun 10, 2024 | In Use | ||
| A9545 | Tositumomab | Bexxar, Iodine i-131 Tositumomab, therapeutic | Per treatment dose | Immunotherapy, Radiopharmaceutical | Radioimmunotherapy | CD20 | No | 2003 | 2014 | Jan 1, 2006 | In Use | |
| A9534 | Tositumomab | Bexxar, Iodine i-131 Tositumomab, therapeutic | per MC | Immunotherapy, Radiopharmaceutical | Radioimmunotherapy | CD20 | No | 2003 | 2014 | Jul 1, 2003 | In Use | |
| S0146 | Peginterferon Alfa-2b | Pegintron, Sylatron | 20 mcg/mL | Immunotherapy | Cytokine | Interferon | No | 2001 | Jul 1, 2005 | Sep 30, 2010 | No Longer Used | |
| J9271 | Pembrolizumab | Keytruda | 1 mg | Immunotherapy | Checkpoint Inhibitor | PD-1 | No | 2014 | Jan 1, 2016 | In Use |
The use of NA indicates that the HCPCS code was Not Available. NA may mean that a) the HCPCS code has
not yet been created (new drug), b) the drug is given as an oral drug or alternative route (only in
specific instances are HCPCS assigned to these medications), or c) the HCPCS could not be found or is
truly not available.
Home